Brief: Fresenius: Receives FDA Approval For Denosumab Biosimilars And Secures Global Settlement

Fresenius SE & Co. KGaA

26/03/2025 16:15

March 26 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE:

FRESENIUS SE - RECEIVES FDA APPROVAL FOR THEIR DENOSUMAB BIOSIMILARS AND SECURES GLOBAL SETTLEMENT

FRESENIUS SE - DENOSUMAB BIOSIMILARS ARE APPROVED FOR ALL INDICATIONS OF THE REFERENCE PRODUCTS PROLIA®* (DENOSUMAB) AND XGEVA®* (DENOSUMAB), RESPECTIVELY

FRESENIUS SE - FRESENIUS’ OPERATING COMPANY REACHED GLOBAL SETTLEMENT WITH AMGEN, ALLOWING LAUNCH OF THESE BIOSIMILARS IN THE US FROM MID-2025 AND IN EUROPE LATER IN H2 OF 2025

Further company coverage: FREG.DE

 (Gdansk Newsroom)

 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))